Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 9/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391128 | 0.89 | PPARG (0.46) | P2RY2PPARGPPARAALDH1A1MAPT | |
| SCHEMBL20544831 | 0.89 | PPARG (0.46) | P2RY2PPARGPPARAALDH1A1MAPT | |
| SCHEMBL391157 | 0.88 | P2RY2 (0.46) | P2RY2PPARGPPARAALDH1A1MAPT | |
| SCHEMBL390753 | 0.88 | P2RY2 (0.46) | P2RY2PPARGPPARAALDH1A1MAPT | |
| SCHEMBL17603813 | 0.88 | P2RY2 (0.46) | P2RY2PPARGPPARAALDH1A1MAPT | |
| SCHEMBL17619244 | 0.86 | P2RY2 (0.45) | P2RY2PPARGPPARAALDH1A1MAPT | |
| SCHEMBL637736 | 0.86 | PPARG (0.46) | P2RY2PPARGPPARAALDH1A1MAPT | |
| SCHEMBL390232 | 0.86 | P2RY2 (0.45) | P2RY2PPARGPPARAALDH1A1MAPT | |
| SCHEMBL27594478 | 0.86 | CTSK (0.52) | PPARGPPARAMAPT | |
| SCHEMBL392217 | 0.86 | PPARG (0.46) | P2RY2PPARGPPARAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312516-A1 | Protein Kinase B Inhibitors | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312516-A1 | Protein Kinase B Inhibitors | PRKAR2B, PRKCB, AKT1 | P2RY2 1136/4885PPARG 3405/4885PPARA 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.